COMPANY PROFILE

Restorbio

Explore full profile

Innovative medicines targeting aging biology to prevent or treat age-related diseases

Boston, United StatesFounded 2016Biotech & Life Sciences

Valuation $100–250M Last recorded · 2017

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Restorbio

resTORbio is a biopharmaceutical company focused on developing innovative medicines that target the biology of aging to prevent or treat age-related diseases. The company operates in the healthcare and pharmaceutical market, primarily serving older adults who are at risk of or suffering from chronic diseases associated with aging. resTORbio's business model revolves around the discovery, development, and commercialization of drugs that modulate specific biochemical pathways, such as the TORC1 pathway, which are believed to regulate aging and its related diseases. The company generates revenue through the development and sale of these therapeutic drugs, as well as through partnerships and collaborations with other pharmaceutical companies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Boston, United States
Employees: 1
Open positions: None listed
Dealroom signal: 57.0/100
Industry: Health, Jobs Recruitment
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Risk Management, Biotechnology, Biotech and Pharma, Silver Economy, Hard Tech, elderly care, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Nov 2017	$40M	$160M	Rock Springs Capital · OrbiMed · Quan Capital · Nest.Bio Labs	—
SERIES AOther financing	Jan 2017	$25M	$100M	PureTech	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Restorbio website traffic

Latest recorded traffic for Restorbio is 340 monthly website visits, down 49.3% over the last three months. Restorbio's team grew 0% over the past year.

Latest monthly visits340 3-month web change-49.3% 1-year team growth0%

Monthly website visitsOct 2017–Jul 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
REReViralAntiviral therapeutics targeting respiratory syncytial virus (RSV)	Stevenage, United Kingdom	Acquired	5	$121M	$525M
BSBio Green Med SolutionClinical-stage biopharma developing cell cycle cancer therapies	Berkeley Heights, United States	Operational
CICircadiaContactless patient monitoring system for predictive healthcare	London, United Kingdom	Operational
TSTouchStream SolutionsHealth information startup company	Rochester, United States	Acquired
INInnoVeinInnoVein is revolutionizing vein care with an implantable valve	San Carlos, United States	Closed
AHAmbio HealthWireless health and activity monitoring solutions especially for chronic patients and the elderly	Stamford, United States	Operational
HEHealthsenseHealthsense \| Remote Monitoring Services	Mendota Heights, United States	Operational
VOVoCarePersonal care and safety products that help elderly and chronically ill patients	Indianapolis, United States	Operational